Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study)

Aim. In this study we evaluated clinical effectiveness and safety of nebulized prostacyclin in patients with Novel Coronavirus Disease (SARS-CoV-2).
Materials and methods: We have included 44 male patients with moderate PCR confirmed SARS-CoV-2 infection in this study. Control group consisted of 23 patients treated with nebulized prostacyclin (PGI₂). besides standard therapy. We compared intensiveness and duration of infectious intoxication syndrome, duration of fever, cough as well as SpO₂ level, complete blood count and chemokine status values.
Results: Statistically significant difference in duration of fever, cough, intensiveness and duration of infectious intoxication syndrome were observed. Lymphocyte and platelet counts were significantly higher in control group We have also noticed significantly lower level of proinflammatory mediators and C4-complement component in control group. Only 1 adverse effect associated with inhaled prostacyclin was reported.
Conclusion. Nebulized prostacyclin showed therapeutic efficacy and good safety profile in adults with moderate COVID-19.

1. Cheng, V. C. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection / V.C. Cheng, S.K. Lau, P.C. Woo, K.Y. Yuen. – DOI:10.1128/ CMR.00023-07. – Текст: электронный // Clinical Microbiology Reviews. – 2007. – №20(4). – С. 660–694. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2176051/ (data obrashhenija 24.06.2020).

2. Lee, N. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong / N. Lee, D. Hui, A. Wu [et. al.]. – DOI: 10.1056/NEJMoa030685. – Текст: электронный // The New England Journal of Medicine. – 2003. – №348. – С. 1986–1994. – URL: https://www.nejm.org/doi/full/10.1056/NEJMoa030685 / (data obrashhenija 24.06.2020).

3. Zaki A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia / A. M. Zaki, S. van Boheemen, T. M. Bestebroer [et. al.]. – DOI: 10.1056/NEJMoa1211721. – Текст: электронный // The New England Journal of Medicine. – 2012. – №367. – С. 1814–1820. – URL: https://www.nejm.org/doi/full/10.1056/NEJMoa1211721 / (data obrashhenija 24.06.2020).

4. de Groot, R.J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group / R.J. de Groot, S.C. Baker, RS. Baric [et. al.]. – DOI: 10.1128/JVI.01244-13. – Текст: электронный // Journal of virology. – 2013. – №87. – С. 7790 – 7792. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700179/ (data obrashhenija 24.06.2020).

5. Huang, C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan / C. Huang, Y. Wang, X. Li [et. al.]. – DOI: 10.1016/S0140-6736(20)30183-5. – Текст: электронный // The Lancet. – 2020. – №395. – С. 497 – 506. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159299/ (дата обращения 24.06.2020).

6. Zajcev, A.A. Prakticheskij opyt vedenija pacientov s novoj koronavirusnoj infekciej COVID-19 v stacionare (predvaritel’nye itogi I rekomendacii) / A.A. Zaycev, S.A. Chernov, E.V. Krjukov [i dr.]. – DOI:10.26295/OS.2020.41.94.014. – Tekst: jelectronnyj // Lechashhij vrach. – 2020. – №6. – S. 74–79. – URL: https://www.ivrach.ru/2020/06/15437595/ (data obrashhenija 24.06.2020).

7. Jain, R. Pharmacological therapy for acute respiratory distress syndrome / R. Jain, A. DalNogare. – DOI: 10.4065/81.2.205. – Текст: электронный // Mayo Clinic Proceedings. – 2006. – №81(2). – С. 205 – 212. – URL: https://www.mayoclinicproceedings.org/article/S0025-6196(11)61672-8/fulltext (data obrashhenija 24.06.2020).

8. Siobal, M. Aerosolized prostacyclins / M. Siobal. – Текст: электронный // Respiratory Care. – 2004. – №49(6). – С. 640 – 652. – URL: http://rc.rcjournal.com/content/49/6/640.short (data obrashhenija 24.06.2020).

9. Wu, C. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods / C. Wu, Y. Liu, Y.Yang [et. al.]. – DOI: 10.1016/j.apsb.2020.02.008. – Текст: электронный // Acta Pharmaceutica Sinica. – 2020. – №10(2). – С. 766 – 788. – URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102550/ (data obrashhenija 24.06.2020).

10. Sibille, M. A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies / M.Sibille, A.Patat, H.Caplain [et. al.]. – DOI: 10.1111/j.1365-2125.2010.03741.x. – Текст: электронный // British journal of clinical pharmacology. – 2010. –№70(5). – С.736–748. – URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997314/#_ffn_sectitle (data obrashhenija 24.06.2020).

11. Hill, N.S. Inhaled therapies for pulmonary hypertension / N.S. Hill, I.R. Preston, K.E. Roberts. – DOI: 10.4187/respcare.03927. – Текст: электронный // Respiratory Care. – 2015. – №60(6). – С. 794 – 802. – URL:http://rc.rcjournal.com/content/60/6/794.short (data obrashhenija 24.06.2020).

12. Wetzel, R.C. Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator // R.C. Wetzel. – DOI: 10.1097/00000542-199506000-00001. – Текст: электронный // Anesthesiology. – 1995. – №82(6). – С. 1315 – 1317. – URL:https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1949625 (data obrashhenija 24.06.2020).

13. Eichelbrönner, O. Aerosolized prostacyclin and inhaled nitric oxide in septic shock / O. Eichelbrönner, H. Reinelt, H. Wiedeck [et. al.]. – DOI: 10.1007/BF02044111. – Текст: электронный // Intensive Care Medicine. – 1996. – №22(9). – С. 880 – 887. – URL: https://link.springer.com/article/10.1007/BF02044111 (дата обращения 24.06.2020).